triple g retatrutide G,” also known as retatrutide, represents the next generation of subcutaneous therapies for metabolic disease. Exciting advancements! Thanks for posting Dr Brian! Triple G 6 mg |

Phase 2 clinical trial data published in the New England Journal of Medicine in 2023 demonstrated substantial mean reductions in body weight in some participants exceeding 20% over 48 weeks alongside improvements in glycaemic control and cardiometabolic markers

GLP-1 & GIP: It retains the appetite suppression, gastric slowing, and insulin-boosting properties of Tirzepatide

doi:10.1007/bf01316798

Your new weekly schedule starts now

GLP-1 receptor agonists like semaglutide work by slowing gastric emptying and signaling fullness to your brainbut the time you inject can influence how well these effects align with your eating patterns

Eng who had strong expertise in RIA for measuring peptides in blood and new methods to isolate peptides and unravel their structures